

Parkinson's Disease

REFERENCES

- Abdel-Wahab MH. Potential neuroprotective effect of t-butylhydroquinone against neurotoxicity: induced by 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-methyl-MPTP) in mice. *J Biochem Mol Toxicol*. 2005;19(1):32-41.
- Abraham S, Soundararajan CC, et al. Erythrocyte antioxidant enzymes in Parkinson's disease. *Indian J Med Res*. 2005 Feb;121(2):111-5.
- Adams CR, Ziegler DK, et al. Mercury intoxication simulating amyotrophic lateral sclerosis. *JAMA*. 1983 Aug 5;250(5):642-3.
- Akbar M, Calderon F, et al. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. *Proc Natl Acad Sci U S A*. 2005 Aug 2;102(31):10858-63.
- American Parkinson Disease Association Inc. Available at: www.apdaparkinson.org. Accessed March 14, 2006.
- Antolin I, Mayo JC, et al. Protective effect of melatonin in a chronic experimental model of Parkinson's disease. *Brain Res*. 2002 Jul 12;943(2):163-73.
- Atasoy HT, Nuyan O, et al. T2-weighted MRI in Parkinson's disease: substantia nigra pars compacta hypointensity correlates with the clinical scores. *Neurol India*. 2004 Sep;52(3):332-7.
- Azuma T, Nagai Y, et al. The effect of dehydroepiandrosterone sulfate administration on patients with multi-infarct dementia. *J Neurol Sci*. 1999 Jan 1;162(1):69-73.
- Bardin JA, Eisen EE, et al. Case-control studies of liver, gallbladder and pancreatic cancer and metalworking fluid exposure in the automobile industry. Paper presented at: 128th Annual Meeting of the American Public Health Association; November 14, 2000; Washington, DC.
- Beal MF. Bioenergetic approaches for neuroprotection in Parkinson's disease. *Ann Neurol*. 2003;53(suppl 3):S39-S47; discussion S47-S8.
- Bender DA, Earl CJ, et al. Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa. *Clin Sci (Lond)*. 1979 Jan;56(1):89-93.
- Benedetti MD, Bower JH, et al. Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. *Neurology*. 2000 Nov 14;55(9):1350-8.
- Brown DJ. Characterizing Risk at Metal Finishing Facilities:1998. Washington DC: Environmental Protection Agency; 1998. May Report EPA/600/R-97/111.
- Castorina M, Ferraris L. Acetyl-L-carnitine affects aged brain receptorial system in rodents. *Life Sci*. 1994;54(17):1205-14.
- Chacon JR, Duran E, et al. Usefulness of olanzapine in the levodopa-induced psychosis in patients with Parkinson's disease [in Spanish]. *Neurologia*. 2002 Jan;17(1):7-11.
- Checkoway H, Powers K, et al. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. *Am J Epidemiol*. 2002 Apr 15;155(8):732-8.
- Chen ST, Chuang JI, et al. Melatonin attenuates MPP+-induced neurodegeneration and glutathione impairment in the nigrostriatal dopaminergic pathway. *J Pineal Res*. 2002 May;32(4):262-9.
- Chong ZZ, Kang JQ, et al. Essential cellular regulatory elements of oxidative stress in early and late phases of apoptosis in the central nervous system. *Antioxid Redox Signal*. 2004 Apr;6(2):277-87.

Clayman CB, ed. The American Medical Association Encyclopedia of Medicine. New York, NY: Random House; 1989.

Coimbra CG, Junqueira VB. High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson's disease patients. *Braz J Med Biol Res.* 2003 Oct;36(10):1409-17.

Cyr M, Calon F, et al. Drugs with estrogen-like potency and brain activity: potential therapeutic application for the CNS. *Curr Pharm Des.* 2000 Aug;6(12):1287-312.

Deleu D. Smoking, alcohol, and coffee consumption preceding Parkinson's disease. *Neurology.* 2001 Apr 10;56(7):984-5.

De Simone R, Ramacci MT, et al. Effect of acetyl-L-carnitine on forebrain cholinergic neurons of developing rats. *Int J Dev Neurosci.* 1991;9(1):39-46.

Duan W, Ladenheim B, et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. *J Neurochem.* 2002 Jan;80(1):101-10.

Fahn S. An open trial of high-dosage antioxidants in early Parkinson's disease. *Am J Clin Nutr.* 1991 Jan;53(suppl 1):S380-S382.

Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. *Ann Neurol.* 1992;32(suppl):S128-S132.

Fariss MW, Zhang JG. Vitamin E therapy in Parkinson's disease. *Toxicology.* 2003 Jul 15;189(1-2):129-46.

Fishman PS, Oyler GA. Significance of the parkin gene and protein in understanding Parkinson's disease. *Curr Neurol Neurosci Rep.* 2002 Jul;2(4):296-302.

Foreman PJ, Perez-Polo JR, et al. Effects of acetyl-L-carnitine treatment and stress exposure on the nerve growth factor receptor (p75NGFR) mRNA level in the central nervous system of aged rats. *Prog Neuropsychopharmacol Biol Psychiatry.* 1995 Jan;19(1):117-33.

Garcia-Escrig M, Bermejo Pareja F, et al. Levodopa-induced psychosis in patients with idiopathic Parkinson disease [in Spanish]. *Med Clin (Barc).* 1999 Feb 27;112(7):245-50.

Gehlen WMJ. Treatment of levodopa psychosis with L-tryptophan. *Dtsch Med Wochenschr.* 1974;99(10):457-63.

Genedani S, Rasio G, et al. Studies on homocysteine and dehydroepiandrosterone sulphate plasma levels in Alzheimer's disease patients and in Parkinson's disease patients. *Neurotox Res.* 2004;6(4):327-32.

Gentry LO. Bacterial resistance. *Orthop Clin North Am.* 1991 Jul;22(3):379-88.

Golbe LI, Farrell TM, et al. Case-control study of early life dietary factors in Parkinson's disease. *Arch Neurol.* 1988 Dec;45(12):1350-3.

Goncharova ND, Oganyan TE, et al. Functions of the hypothalamo-hypophyseal-adrenal system in aging female monkeys. *Neurosci Behav Physiol.* 2000 Nov;30(6):717-21.

Gotz ME, Gerstner A, et al. Altered redox state of platelet coenzyme Q10 in Parkinson's disease. *J Neural Transm.* 2000;107(1):41-8.

Goyer RA. Toxic and essential metal interactions. *Annu Rev Nutr.* 1997;17:37-50.

Growdon JH, Melamed E, et al. Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease. *Life Sci.* 1982 Mar 8;30(10):827-32.

Heller A, Won L, et al. Long-chain fatty acids increase cellular dopamine in an immortalized cell line (MN9D) derived from mouse mesencephalon. *Neurosci Lett.* 2005 Mar 7;376(1):35-9.

Hirsch MA, Toole T, et al. The effects of balance training and high-intensity resistance training on persons with idiopathic Parkinson's disease. *Arch Phys Med Rehabil.* 2003 Aug;84(8):1109-17.

Hsu M, Srinivas B, et al. Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson's disease. *J Neurochem*. 2005 Mar;92(5):1091-103.

Jimenez-Jimenez FJ, Molina JA, et al. Serum levels of coenzyme Q10 in patients with Parkinson's disease. *J Neural Transm*. 2000;107(2):177-81.

Kasper DL, Braunwald E, et al, eds. *Harrison's Principles of Internal Medicine*. 16th ed. New York, NY: McGraw-Hill; 2004.

Khaldy H, Escames G, et al. Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion. *Neurobiol Aging*. 2003;24:491-500.

Kidd PM. Neurodegeneration from mitochondrial insufficiency: nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management. *Altern Med Rev*. 2005 Dec;10(4):268-93.

Koller WC, Cersosimo MG. Neuroprotection in Parkinson's disease: an elusive goal. *Curr Neurol Neurosci Rep*. 2004 Jul;4(4):277-83.

Kurth MC, Tetrad JW, et al. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. *Neurology*. 1993 May;43(5):1036-9.

Linert W, Jameson GN. Redox reactions of neurotransmitters possibly involved in the progression of Parkinson's disease. *J Inorg Biochem*. 2000 Apr;79(1-4):319-26.

Logroscino G, Marder K, et al. Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. *Ann Neurol*. 1996 Jan;39(1):89-94.

Lyons KE, Pahwa R. Long-term benefits in quality of life provided by bilateral subthalamic stimulation in patients with Parkinson's disease. *J Neurosurg*. 2005;103:252-5.

Mally J, Stone TW. The effect of theophylline on parkinsonian symptoms. *J Pharm Pharmacol*. 1994 Jun;46(6):515-7.

Mazzio E, Huber J, et al. Effect of antioxidants on L-glutamate and N-methyl-4-phenylpyridinium ion induced-neurotoxicity in PC12 cells. *Neurotoxicology*. 2001 Apr;22(2):283-8.

McFadden SA. Phenotypic variation in xenobiotic metabolism and adverse environmental response: focus on sulfur-dependent detoxification pathways. *Toxicology*. 1996 Jul 17;111(1-3):43-65.

Mizuta E, Kuno S. Rotations induced by L-dopa in parkinsonian rats are reduced by an ingestion of amino acids. *J Neural Transm Park Dis Dement Sect*. 1993;6(3):211-4.

Muller T, Buttner T, et al. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. *Neurosci Lett*. 2003 May 8;341(3):201-4.

Mytilineou C, Han SK, et al. Toxic and protective effects of L-dopa on mesencephalic cell cultures. *J Neurochem*. 1993 Oct;61(4):1470-8.

Nadlinger K, Birkmayer J, et al. Influence of reduced nicotinamide adenine dinucleotide on the production of interleukin-6 by peripheral human blood leukocytes. *Neuroimmunomodulation*. 2001;9(4):203-8.

Pardo B, Mena MA, et al. Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. *Brain Res*. 1995 Jun 5;682(1-2):133-43.

PDR. *The PDR Pocket Guide to Prescription Drugs*. 5th ed. New York, NY: Pocket Books/Simon & Schuster; 2002.

Petroni ML, Albani G, et al. Body composition in advanced-stage Parkinson's disease. *Acta Diabetol*. 2003 Oct;40(suppl 1):S187-S190.

Pettegrew JW, Levine J, et al. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. *Mol Psychiatry*. 2000 Nov;5(6):616-32.

Philpott DJ, Girardin SE, et al. Innate immune responses of epithelial cells following infection with bacterial pathogens. *Curr Opin Immunol*. 2001 Aug;13(4):410-6.

Powers KM, Smith-Weller T, et al. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. *Neurology*. 2003 Jun 10;60(11):1761-6.

Purves D, Augustine GJ, et al, eds. *Neuroscience*. 2nd ed. Sunderland, Mass: Sinauer Associates, Inc; 2001.

Rabey JM, Vardi J, et al. L-tryptophan administration in L-dopa-induced hallucinations in elderly Parkinsonian patients. *Gerontology*. 1977;23(6):438-44.

Rascol O, Brooks DJ, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa: 056 Study Group. *N Engl J Med*. 2000 May 18;342(20):1484-91.

Riederer P. L-dopa competes with tyrosine and tryptophan for human brain uptake. *Nutr Metab*. 1980;24(6):417-23.

Roghani M, Behzadi G. Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. *Brain Res*. 2001 Feb 16;892(1):211-7.

Ross GW, Petrovitch H, et al. Parkinsonian signs and substantia nigra neuron density in decedents elders without PD. *Ann Neurol*. 2004 Oct;56(4):532-9.

Sakagami H, Satoh K, et al. Interaction between sodium ascorbate and dopamine. *Free Radic Biol Med*. 1998 Dec;25(9):1013-20.

Sandyk R. L-tryptophan in neuropsychiatric disorders: a review. *Int J Neurosci*. 1992 Nov;67(1-4):127-44.

Sandyk R, Pardeshi R. Pyridoxine improves drug-induced parkinsonism and psychosis in a schizophrenic patient. *Int J Neurosci*. 1990 Jun;52(3-4):225-32.

Schulz JB, Henshaw DR, et al. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. *Exp Neurol*. 1995 Apr;132(2):279-83.

Seitz G, Gebhardt S, et al. Ascorbic acid stimulates DOPA synthesis and tyrosine hydroxylase gene expression in the human neuroblastoma cell line SK-N-SH. *Neurosci Lett*. 1998 Mar 6;244(1):33-6.

Shults CW, Flint Beal M, et al. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. *Exp Neurol*. 2004 Aug;188(2):491-4.

Shults CW, Haas RH, et al. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. *Ann Neurol*. 1997 Aug;42(2):261-4.

Shults CW, Oakes D, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. *Arch Neurol*. 2002 Oct;59(10):1541-50.

Silverman, HM Ed. *The Pill Book*. 9th ed. New York, New York: Bantam Books: CMD Publishing; 2000.

Smargiassi A, Mutti A, et al. A case-control study of occupational and environmental risk factors for Parkinson's disease in the Emilia-Romagna region of Italy. *Neurotoxicology*. 1998 Aug;19(4-5):709-12.

Soto-Otero R, Mendez-Alvarez E, et al. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. *J Neurochem*. 2000 Apr;74(4):1605-12.

Steele PE, Tang PH, et al. Clinical laboratory monitoring of coenzyme Q10 use in neurologic and muscular diseases. *Am J Clin Pathol*. 2004 Jun;121(suppl):S113-S120.

Sullivan A, Edlund C, et al. Effect of antimicrobial agents on the ecological balance of human microflora. *Lancet Infect Dis*. 2001 Sep;1(2):101-14.

Sutoo D, Akiyama K. Regulation of brain function by exercise. *Neurobiol Dis*. 2003 Jun;13(1):1-14. Review.

Tagliabue G, Navarra D, et al. Acetyl-L-carnitine treatment increases nerve growth factor levels and choline acetyltransferase activity in the central nervous system of aged rats. *Exp Gerontol.* 1994 Jan-Feb;29(1):55-66.

Tancredi C. Role of human microflora in health and disease. *Eur J Clin Microbiol Infect Dis.* 1992 Nov;11(11):1012-5.

Van Vaerenbergh J, Vranken R, et al. The influence of rotational exercises on freezing in Parkinson's disease. *Funct Neurol.* 2003 Jan-Mar;18(1):11-6.

Weinreb O, Mandel S, et al. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. *J Nutr Biochem.* 2004 Sep;15(9):506-16.

Yapa SC. Detection of subclinical ascorbate deficiency in early Parkinson's disease. *Public Health.* 1992 Sep;106(5):393-5.

Young G, Conquer J. Omega-3 fatty acids and neuropsychiatric disorders. *Reprod Nutr Dev.* 2005 Jan;45(1):1-28.

Zecca L, Youdim MB, et al. Iron, brain ageing and neurodegenerative disorders. *Nat Rev Neurosci.* 2004 Nov;5(11):863-73.

Zisapel N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. *Cell Mol Neurobiol.* 2001 Dec;21(6):605-16.

Zuber M, Alperovitch A. Parkinson's disease and environmental factors [in French]. *Rev Epidemiol Sante Publique.* 1991;39(4):373-87.

All Contents Copyright © 1995-2009 Life Extension Foundation All rights reserved.

LifeExtension®

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.